Pozelimab (REGN3918) + Cemdisiran ( DrugBank: Pozelimab, Cemdisiran )


1 disease
IDDisease name (Link within this page)Number of trials
11Myasthenia gravis1

11. Myasthenia gravis


Clinical trials : 315 Drugs : 232 - (DrugBank : 77) / Drug target genes : 46 - Drug target pathways : 126
No.TrialIDDate_
enrollment
Date_
registration
Public_titleScientific_titleConditionInterventionPrimary_
sponsor
Secondary_
sponsor
Recruitment_
Status
Inclusion_
agemin
Inclusion_
agemax
Inclusion_
gender
Target_
size
PhaseCountries
1NCT05070858
(ClinicalTrials.gov)
September 30, 202127/9/2021A Study to Examine the Efficacy and Safety of Pozelimab and Cemdisiran Combination Therapy in Adult Patients With Symptomatic Generalized Myasthenia GravisEfficacy and Safety of Pozelimab and Cemdisiran Combination Therapy in Patients With Symptomatic Generalized Myasthenia GravisGeneralized Myasthenia GravisDrug: Pozelimab (REGN3918) + Cemdisiran;Drug: Cemdisiran;Other: PlaceboRegeneron PharmaceuticalsNULLNot yet recruiting18 YearsN/AAll210Phase 3NULL